ALKERMES, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.alkermes.com

Clinical Trials

Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery

Phase 3

Terminated

Conditions: Laparoscopic Surgery

Interventions: Drug: N1539
Drug: Ketorolac Tromethamine
Drug: Placebo

First Posted Date: 2011-09-19

Last Posted Date: 2012-03-14

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 50

Registration Number: NCT01436032

Locations: 🇺🇸
Lotus Clinical Research LLC, Pasadena, California, United States

ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry

Completed

Conditions: Opioid Dependence

First Posted Date: 2011-08-24

Last Posted Date: 2018-11-16

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 403

Registration Number: NCT01422837

Locations: 🇺🇸
Innovation Laboratory/PEARL, Johnson City, Tennessee, United States
🇺🇸
Arkansas Psychiatric Clinc, Little Rock, Arkansas, United States
🇺🇸
Psychotherapy Services, Etc., Groton, Connecticut, United States

and more 27 locations

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

Phase 2

Completed

Conditions: OIC

Interventions: Drug: Placebo
Drug: ALKS 37

First Posted Date: 2011-08-16

Last Posted Date: 2012-08-07

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 91

Registration Number: NCT01418092

Locations: 🇺🇸
Alkermes Investigational Site, Bellevue, Washington, United States

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: ALKS 5461

First Posted Date: 2011-06-27

Last Posted Date: 2011-08-23

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 32

Registration Number: NCT01381107

Locations: 🇺🇸
Comprehensive NeuroScience, Inc., Atlanta, Georgia, United States

ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

Phase 2

Completed

Conditions: Opioid-induced Constipation

Interventions: Drug: Placebo
Drug: ALKS 37

First Posted Date: 2011-06-27

Last Posted Date: 2012-06-13

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 157

Registration Number: NCT01382797

Locations: 🇺🇸
Alkermes Study Site, San Antonio, Texas, United States
🇺🇸
Alkermes Investigational Site, De Land, Florida, United States

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

Phase 1

Completed

Conditions: Cocaine Abuse

Interventions: Drug: ALKS 33-BUP
Drug: ALKS 33
Drug: Placebo

First Posted Date: 2011-06-03

Last Posted Date: 2012-03-09

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 33

Registration Number: NCT01366001

Locations: 🇺🇸
Alkermes Study Site, Overland Park, Kansas, United States

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Phase 2

Completed

Conditions: Opiate Dependence

Interventions: Drug: Medisorb naltrexone 75 mg
Drug: Medisorb naltrexone 150 mg
Drug: Medisorb naltrexone 300 mg
Drug: Hydromorphone (10 mg/mL)
Drug: Naloxone Challenge and Oral Naltrexone Tolerability Testing

First Posted Date: 2010-10-13

Last Posted Date: 2017-01-11

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 27

Registration Number: NCT01218984

ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)

Phase 3

Completed

Conditions: Alcohol Dependence

Interventions: Drug: Medisorb naltrexone 380 mg
Drug: Medisorb naltrexone 190 mg

First Posted Date: 2010-10-13

Last Posted Date: 2010-12-24

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 332

Registration Number: NCT01218971

ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

Phase 3

Completed

Conditions: Alcoholism

Interventions: Drug: Placebo matching Medisorb naltrexone 190 mg
Drug: Placebo matching Medisorb naltrexone 380 mg
Drug: Medisorb naltrexone 190 mg
Drug: Medisorb naltrexone 380 mg

First Posted Date: 2010-10-13

Last Posted Date: 2017-07-11

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 624

Registration Number: NCT01218958

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Phase 3

Completed

Conditions: Alcoholism

Interventions: Drug: Medisorb naltrexone 380 mg
Drug: Oral naltrexone 50 mg

First Posted Date: 2010-10-13

Last Posted Date: 2011-01-04

Lead Sponsor: Alkermes, Inc.

Target Recruit Count: 436

Registration Number: NCT01218997

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy